In 2020, RET‐selective inhibitors pralsetinib and selpercatinib received clinical approval for RET fusion‐positive NSCLC, RET‐mutant MTC, and RET fusion‐positive thyroid cancer based on the results of the phase I/II ARROW study and the phase I/II LIBRETTO‐001 trial, respectively.213. This evidence concerns the gene RET and non-small cell lung carcinoma.